I agree HouseofCards. Normally, phase 2 is where you learn about dosing, and which endpoints are the most effective, etc. Cytodyn didn't get the benefit of that research. Their trial was combined into a phase 2b/3, "all or nothing" shot, at a time when little was known about the disease. They have learned a lot about the drug in a very short time. Yes, it's taking longer than we hoped, but given a real chance with a large trial, the effect should not only be obvious to a layperson but statistically and clinically significant. A lot of the EIND patients had more than 2 doses. We should see similar results with critical patients now.
News 
Market Data 
Discover 
